On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...